Mermaid Medical Group® Achieves Zero Non-Conformities in ISO 14001 Environmental Audit
Mermaid Medical Group® is proud to share that it has successfully passed its ISO 14001 audit with zero non-conformities identified.
Mermaid Medical Group is excited to introduce its latest product addition: the Full Core Biopsy Device - designed with both optimal biopsy sample quality and user ergonomics in mind.
Copenhagen, Denmark, June, 2025
The Full Core Biopsy Device offers millimeter-by-millimeter adjustable throw length, giving clinicians precise control when targeting different organs. This flexibility makes it ideal for image-guided biopsies of the lung, kidney, liver, and thyroid, whether performed under ultrasound or CT guidance. Its ultra-lightweight design - among the lightest full core biopsy solutions on the market - also makes it particularly well-suited for use in CT gantry setups. Its ergonomic design enables true one-handed operation, supporting ease of use and improved procedural control.
The device also features a tri-axial cutting system and a pincher-style internal capture mechanism embedded directly into the outer cannula. This design keeps biopsy samples intact, reducing the risk of crush damage and ensuring they are suitable for accurate pathological evaluation and diagnosis. With minimized dead space compared to similar devices, the system also contributes to smoother workflows and procedural efficiency.
“We’ve been searching for a full core biopsy device for some time, and we’re excited to now offer one that consistently delivers high-quality samples,” says Michael Kronby, Category Manager at Mermaid Medical. “The millimeter-by-millimeter adjustable throw length gives clinicians full control when targeting different organs, and it’s ultra lightweight, which makes it stable even in CT gantry setups. Combined with the internal capture system that keeps samples intact, this device supports both procedural efficiency and diagnostic accuracy.”
In recent weeks, Mermaid Medical has carried out comprehensive training for its sales teams, ensuring they are fully equipped to advise clients on the new device. This focus on education and collaboration reflects Mermaid Medical’s commitment to supporting healthcare professionals and enhancing patient care.
“Ensuring our sales teams are fully prepared means we can provide partners with expert advice and confidence in using our new device,” Kronby adds. “This training is key to helping healthcare professionals achieve the best outcomes for their patients.”
One of those who benefited from the product training is Katerina Shaw, Clinical Sales and Export Manager at Mermaid Medical. She recently presented the device at a conference in the Netherlands - you can watch her introduction in the video below. With her background in nursing, Katerina brings valuable clinical insight and a patient-centered perspective to her role, helping healthcare professionals apply the device effectively in real-world settings.
For more information about the Full Core Biopsy Device, click here, or reach out to our Customer Service team.
Media Contact:
Anne Sandgaard
Mermaid Medical Group
+45 2194 8508
asa@mermaidmedical.com
Mermaid Medical Group® is proud to share that it has successfully passed its ISO 14001 audit with zero non-conformities identified.
Mermaid Medical Group® is pleased to announce an exclusive distribution agreement with MicroPort® for two cardiovascular devices: the VitaFlow Liberty™ Aortic Valve & Delivery System and Anchorman™ for LAAC procedures.
Mermaid Medical Group® is excited to announce that our partner, Danderyd Hospital in Sweden, is now offering microwave ablation (MWA) as a treatment for uterine fibroids, following the success of several clinical studies.